Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma
Initial Series A raise of $350 million funding Areteia Phase III development program of dexpramipexole in eosinophilic asthma, including three ongoing Phase III clinical trials Additional funding of $75 million will support significant expansion of…